- Previous Close
13.02 - Open
13.04 - Bid 12.97 x --
- Ask 12.98 x --
- Day's Range
12.86 - 13.15 - 52 Week Range
10.75 - 16.40 - Volume
2,379,780 - Avg. Volume
10,335,654 - Market Cap (intraday)
20.984B - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.22 - Earnings Date --
- Forward Dividend & Yield 0.12 (0.88%)
- Ex-Dividend Date Jul 7, 2023
- 1y Target Est
16.32
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. The company provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium, cisatracurium, fulvestrant, doxercalciferol, milrinone lactate, fondaparinux sodium, phenylephrine, gemcitabine, levoleucovorin, carboplatin, cytarabine, bleomycin, topotecan hydrochloride, bendamustine HCL, bortezomib, clofarabine, busulfan, dactinomycin, azacitidine, mycophenolate mofetil, tigecycline, glycopyrrolate, melphalan, daptomycin, decitabine, haloperidol decanoate, carmustine, bivalirudin, dexmedetomidine, and neostigmine methylsulfate injections. It also offers isosulfan blue, succinylcholine chloride, furosemide, regadenoson, voriconazole, ganirelix acetate, eptifibatide, enoxaparin sodium, mitomycin, vancomycin, micafungin sodium, docetaxel, nelarabine, pemetrexed, rocuronium bromide, zoledronic acid, thiamine, fluorouracil, perixafor, thiotepa, pantoprazole sodium, glatiramer acetate, and bupivacaine hydrochloride injections. The company was founded in 2000 and is based in Nanjing, China.
www.nkf-pharma.com1,451
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 603707.SS
Performance Overview: 603707.SS
Trailing total returns as of 6/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603707.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603707.SS
Valuation Measures
Market Cap
20.60B
Enterprise Value
21.16B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.57
Price/Book (mrq)
3.44
Enterprise Value/Revenue
5.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-9.50%
Return on Assets (ttm)
-3.39%
Return on Equity (ttm)
-5.52%
Revenue (ttm)
3.63B
Net Income Avi to Common (ttm)
-344.58M
Diluted EPS (ttm)
-0.22
Balance Sheet and Cash Flow
Total Cash (mrq)
2.16B
Total Debt/Equity (mrq)
45.64%
Levered Free Cash Flow (ttm)
1.38B